Protocols

NeuroVive shares crater on PhII flop; F-Prime contributes $7.5M in startup cash for Akriveia

Shares of NeuroVive Pharmaceuticals tanked Thursday after the small Swedish biotech reported that it is scrapping its cyclosporine formulation in acute kidney injury after watching it flop in Phase II. The stock (STO:NVP) plunged 44% during the day.

Thousand Oaks, CA-based Akriveia Therapeutic bagged a $7.5 million Series A investment from F-Prime Capital Partners. The biotech is working on immuno-oncology programs. Thomas Beck and Ben Auspitz of F-Prime Capital Partners will join Akriveia’s board alongside Akriveia’s CEO, Simon Tomlinson, with Beck becoming chairman of the board.

South Korea’s Celltrion says that its biosimilar of Rituxan performed well in a Phase III study, setting up a review of the data at AACR.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Endpoints News Webinar

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->